{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '35', 'Version Date: 07/22/2019', 'introduces additional data which may bias an investigator if it is not routinely or serially', 'performed.', 'Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a', 'method of measurement. Ultrasound examinations cannot be reproduced in their entirety for', 'independent review at a later date and, because they are operator dependent, it cannot be', 'guaranteed that the same technique and measurements will be taken from one assessment to the', 'next. If new lesions are identified by ultrasound in the course of the study, confirmation by CT', 'or MRI is advised. If there is concern about radiation exposure at CT, MRI may be used instead', 'of CT in selected instances.', 'Endoscopy, Laparoscopy: The utilization of these techniques for objective tumor evaluation is', 'not advised. However, such techniques may be useful to confirm complete pathological', 'response when biopsies are obtained or to determine relapse in trials where recurrence following', 'complete response (CR) or surgical resection is an endpoint.', 'Tumor markers: Tumor markers alone cannot be used to assess response. If markers are initially', 'above the upper normal limit, they must normalize for a patient to be considered in complete', 'clinical response. Specific guidelines for both CA-125 response (in recurrent ovarian cancer)', 'and PSA response (in recurrent prostate cancer) have been published [JNCI96:487-488, 2004; J', 'Clin Oncol 17, 3461-3467, 1999; J Clin Oncol 26:1148-1159, 2008]. In addition, the', 'Gynecologic Cancer Intergroup has developed CA-125 progression criteria which are to be', 'integrated with objective tumor assessment for use in first-line trials in ovarian cancer [JNCI', '92:1534-1535, 2000].', 'Cytology, Histology: These techniques can be used to differentiate between partial responses', '(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as', 'germ cell tumors, where known residual benign tumors can remain).', 'The cytological confirmation of the neoplastic origin of any effusion that appears or worsens', 'during treatment when the measurable tumor has met criteria for response or stable disease is', 'mandatory to differentiate between response or stable disease (an effusion may be a side effect of', 'the treatment) and progressive disease.', 'FDG-PET: While FDG-PET response assessments need additional study, it is sometimes', 'reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in', \"assessment of progression (particularly possible 'new' disease). New lesions on the basis of\", 'FDG-PET imaging can be identified according to the following algorithm:', 'a. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD', 'based on a new lesion.', 'b. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-', 'PET at follow-up corresponds to a new site of disease confirmed by CT, this is PD. If the', 'positive FDG-PET at follow-up is not confirmed as a new site of disease on CT,', 'additional follow-up CT scans are needed to determine if there is truly progression', 'occurring at that site (if so, the date of PD will be the date of the initial abnormal FDG-', 'PET scan). If the positive FDG-PET at follow-up corresponds to a pre-existing site of', 'disease on CT that is not progressing on the basis of the anatomic images, this is not PD.']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '36', 'Version Date: 07/22/2019', 'c.', 'FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in', 'cases where a residual radiographic abnormality is thought to represent fibrosis or', 'scarring. The use of FDG-PET in this circumstance should be prospectively described in', 'the protocol and supported by disease-specific medical literature for the indication.', 'However, it must be acknowledged that both approaches may lead to false positive CR', 'due to limitations of FDG-PET and biopsy resolution/sensitivity.', 'Note: A \"positive\\' FDG-PET scan lesion means one which is FDG avid with an uptake greater', 'than twice that of the surrounding tissue on the attenuation corrected image.', '8.2.2 Response Criteria', '8.2.2.1 Evaluation of Target Lesions', 'Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes', '(whether target or non-target) must have reduction in short axis to <10 mm.', 'Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions,', 'taking as reference the baseline sum of diameters.', 'Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions,', 'taking as reference the smallest sum on study (this includes the baseline sum if that is the', 'smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an', 'absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also', 'considered progressions).', 'Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to', 'qualify for PD, taking as reference the smallest sum of diameters while on study.', 'Evaluation of Non-Target Lesions', 'Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor', 'marker level. All lymph nodes must be non-pathological in size (<10 mm short axis).', 'Note: If tumor markers are initially above the upper normal limit, they must normalize for a', 'patient to be considered in complete clinical response.', 'Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or maintenance of tumor', 'marker level above the normal limits.', 'Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal', 'progression of existing non-target lesions. Unequirocal progression should not normally trump', 'target lesion status. It must be representative of overall disease status change, not a single lesion', 'increase.', 'Although a clear progression of \"non-target\" lesions only is exceptional, the opinion of the', 'treating physician should prevail in such circumstances, and the progression status should be', 'confirmed at a later time by the review panel (or Principal Investigator).', '8.2.2.2 Evaluation of Best Overall Response', 'The best overall response is the best response recorded from the start of the treatment until', 'disease progression/recurrence (taking as reference for progressive disease the smallest']\n\n###\n\n", "completion": "END"}